Paul M. Sondel, MD, PhD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
Dr. Sondel has been a leader in scientific policy through multiple national committee roles, including The National Institutes of Health, The American Cancer Society, The Children's Oncology Group (COG), The National Cancer Institute, where he was a member of the Board of Scientific Counselors, and St. Jude's Children’s Research Hospital, where he was the Chair of their Scientific Advisory Committee and is now chair of their cancer center's external advisory board.
UW Health Clinics
UW School of Medicine and Public Health
|Department of Pediatrics|
Professional Certifications and Education
Pediatric Oncology, Midwest Children's Cancer Center at Children's Hospital of Wisconsin, Milwaukee, WI
University of Wisconsin Hospital and Clinics, Madison, WI
University of Minnesota Hospital and Clinics
Harvard Medical School, Boston, MA, 1977
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.
Programs & Conditions
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Adrenocortical carcinoma
- Aplastic Anemia
- Atypical Teratoid/Rhabdoid tumor
- Bleeding Disorders
- Brain Stem Glioma
- Chronic Myeloid Leukemia
- Congenital Hemolytic Anemias
- Cyclic Neutropenia
- Diamond-Blackfan Syndrome
- Endocrine Tumors
- Ewing Sarcoma
- Fanconi's Anemia
- Germ Cell Tumors
- Hemophagocytic Lymphohistiocytosis
- Hemophilia A
- Hemophilia B
- Hereditary Spherocytosis
- Hodgkin's Disease
- Immune Thrombocytopenc Purpura
- Juvenile Myelomonocytic Leukemia
- Kostmann Syndrome
- Langerhans' Cell Histiocytosis
- Myelodysplastic Syndromes
- Neurocutaneous Syndrome
- Non-Hodgkin Lymphomas
- Optic Glioma
- Paroxysmal Nocturnal Hemoglobinuria
- Pediatric Cancer
- Pediatric Sickle Cell Disease
- Shwachman-Diamond Syndrome
- Sturge-Weber Syndrome
- Thalassemia Syndromes
- Thyroid Tumors
- Tuberous Sclerosis
- Vascular malformations
- Von Willebrand Disease
- VonHippel-Lindau Disease
- Wilms Tumor
Dr. Sondel's research has emphasized the translation of laboratory innovations into clinical progress. His laboratory has pursued the biology of graft-versus-leukemia reactions, activation of anti-tumor immune destruction with Interleukin-2 and the use of tumor reactive monoclonal antibodies to facilitate tumor killing by lymphocytes. These studies have all moved into clinical testing led by Dr. Sondel at UW, and in national studies he has led through the Children’s Oncology Group (COG).
He has published more than 360 scientific articles and chapters, and his laboratory has provided training for 58 graduate students and post-doctoral fellows.
Albertini MR Ranheim EA Zuleger CL Sondel PM Hank JA Bridges A Newton MA McFarland T Collins J Clements E Henry MB Neuman HB Weber S Whalen G Galili U .
Phase I study to evaluate toxicity and feasibility of intratumoral injection of α-gal glycolipids in patients with advanced melanoma. Cancer Immunol Immunother. 2016 Aug;65(8):897-907
[PubMed ID: 27207605]
Wang W Erbe AK Alderson KA Phillips E Gallenberger M Gan J Campana D Hank JA Sondel PM .
Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion. Cancer Immunol Immunother. 2016 Jul 8;
[PubMed ID: 27392940]
Morris ZS Guy EI Francis DM Gressett MM Werner LR Carmichael LL Yang RK Armstrong EA Huang S Navid F Gillies SD Korman A Hank JA Rakhmilevich AL Harari PM Sondel PM .
In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments. Cancer Res. 2016 Jul 1;76(13):3929-41
[PubMed ID: 27197149]
Neri D Sondel PM .
Immunocytokines for cancer treatment: past, present and future. Curr Opin Immunol. 2016 Jun;40:96-102
[PubMed ID: 27060634]
Kohrt HE Tumeh PC Benson D Bhardwaj N Brody J Formenti S Fox BA Galon J June CH Kalos M Kirsch I Kleen T Kroemer G Lanier L Levy R Lyerly HK Maecker H Marabelle A Melenhorst J Miller J Melero I Odunsi K Palucka K Peoples G Ribas A Robins H Robinson W Serafini T Sondel P Vivier E Weber J Wolchok J Zitvogel L Disis ML Cheever MA .
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. J Immunother Cancer. 2016;4:15
[PubMed ID: 26981245]
Erbe AK Wang W Gallenberger M Hank JA Sondel PM .
Genotyping Single Nucleotide Polymorphisms and Copy Number Variability of the FCGRs Expressed on NK Cells. Methods Mol Biol. 2016;1441:43-56
[PubMed ID: 27177655]
Jensen JL Rakhmilevich A Heninger E Broman AT Hope C Phan F Miyamoto S Maroulakou I Callander N Hematti P Chesi M Bergsagel PL Sondel P Asimakopoulos F .
Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma. Cancer Immunol Res. 2015 Aug;3(8):881-90
[PubMed ID: 25941352]
Shi Y Felder MA Sondel PM Rakhmilevich AL .
Synergy of anti-CD40, CpG and MPL in activation of mouse macrophages. Mol Immunol. 2015 Aug;66(2):208-15
[PubMed ID: 25829245]
Goldberg JL Sondel PM .
Enhancing Cancer Immunotherapy Via Activation of Innate Immunity. Semin Oncol. 2015 Aug;42(4):562-72
[PubMed ID: 26320061]
McDowell KA Hank JA DeSantes KB Capitini CM Otto M Sondel PM .
NK cell-based immunotherapies in Pediatric Oncology. J Pediatr Hematol Oncol. 2015 Mar;37(2):79-93
[PubMed ID: 25590232]
Wang W Erbe AK Hank JA Morris ZS Sondel PM .
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy. Front Immunol. 2015;6:368
[PubMed ID: 26284063]
Sheridan RT Hudon J Hank JA Sondel PM Kiessling LL .
Rhamnose glycoconjugates for the recruitment of endogenous anti-carbohydrate antibodies to tumor cells. Chembiochem. 2014 Jul 7;15(10):1393-8
[PubMed ID: 24909955]
Navid F Sondel PM Barfield R Shulkin BL Kaufman RA Allay JA Gan J Hutson P Seo S Kim K Goldberg J Hank JA Billups CA Wu J Furman WL McGregor LM Otto M Gillies SD Handgretinger R Santana VM .
Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol. 2014 May 10;32(14):1445-52
[PubMed ID: 24711551]
Capitini CM Otto M DeSantes KB Sondel PM .
Immunotherapy in pediatric malignancies: current status and future perspectives. Future Oncol. 2014;10(9):1659-78
[PubMed ID: 25145434]
Qu X Felder MA Perez Horta Z Sondel PM Rakhmilevich AL .
Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model. Int Immunopharmacol. 2013 Dec;17(4):1141-7
[PubMed ID: 24201083]
Yang RK Kalogriopoulos NA Rakhmilevich AL Ranheim EA Seo S Kim K Alderson KL Gan J Reisfeld RA Gillies SD Hank JA Sondel PM .
Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival. Cancer Immunol Immunother. 2013 Aug;62(8):1303-13
[PubMed ID: 23661160]
Alderson KL Luangrath M Elsenheimer MM Gillies SD Navid F Rakhmilevich AL Sondel PM .
Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG. Cancer Immunol Immunother. 2013 Apr;62(4):665-75
[PubMed ID: 23151945]
Van De Voort TJ Felder MA Yang RK Sondel PM Rakhmilevich AL .
Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice. J Immunother. 2013 Jan;36(1):29-40
[PubMed ID: 23211623]
Albertini MR Hank JA Gadbaw B Kostlevy J Haldeman J Schalch H Gan J Kim K Eickhoff J Gillies SD Sondel PM .
Phase II trial of hu14.18-IL2 for patients with metastatic melanoma. Cancer Immunol Immunother. 2012 Dec;61(12):2261-71
[PubMed ID: 22678096]
Rakhmilevich AL Baldeshwiler MJ Van De Voort TJ Felder MA Yang RK Kalogriopoulos NA Koslov DS Van Rooijen N Sondel PM .
Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects. Cancer Immunol Immunother. 2012 Oct;61(10):1683-97
[PubMed ID: 22392192]